Preferred Label : Nogapendekin Alfa Inbakicept;
NCIt synonyms : IL-15N72D-IL-15RaSU/Fc; Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803; IL-15N72D/IL-15Ra-Fc; IL-15N72D:IL-15RaSu/Fc Fusion Complex; Inbakicept Nogapendekin Alfa Fusion Complex; Fusion Protein Consisting of IL-15N72D and IL-15RASU/FC; Nogapendekin Alfa Inbakicept-pmln; IL-15N72D:IL-15REC-SU/FC Soluble Complex I;
NCIt definition : A fusion protein soluble complex and interleukin-15 (IL-15) receptor agonist composed
of nogapendekin alfa, a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D)
and inbakicept, a fusion protein containing a dimeric IL-15 receptor alpha (IL-15Ra)
sushi domain fused to human immunoglobulin G1 (IgG1) Fc (IL15Ra-Fc; IL-15RaSu-IgG1
Fc), with potential antineoplastic activity. Each fully assembled nogapendekin alfa
inbakicept complex consists of a single inbakicept and two nogapendekin alfa components.
Upon intravesicular administration, nogapendekin alfa inbakicept binds to the IL-2/IL-15
beta-common (bc) gamma chain (gc) receptor on natural killer (NK), CD8 T lymphocytes
and CD4 T helper cells, which activates and increases the levels of NK cells, cytotoxic
T-cells and memory T-cells. The memory T-cells enhance the secretion of the cytokine
interferon-gamma (IFN-g), which further potentiates the immune response against tumor
cells. This may increase tumor cell killing and decrease tumor cell proliferation.
IL-15 regulates CD8 T and NK cell development, activation and proliferation. By coupling
IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased
ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as
compared to IL-15 alone.;
UNII : 7TK323DLA0;
CAS number : 1850381-92-8;
Drug name : Anktiva;
Molecule name : N-803; N 803; ALT-803; ALT 803;
NCI Metathesaurus CUI : CL1927683;
Origin ID : C205507;
chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- is_component_of_chemotherapy_regimen
